Search Within

Ronglai Shen

  1. "Sarcoma Service"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Department of Pathology and Laboratory Medicine (6)
  4. Epidemiology and Biostatistics (6)
  5. GSK Faculty (6)
  6. Human Oncology and Pathogenesis Program (6)

More Groups

People
  1. Marc Ladanyi (5)
  2. Sandra D'Angelo (5)
  3. Gregory Riely (3)
  4. Mark Kris (3)
  5. Maureen Zakowski (3)
  6. Yelena Janjigian (3)

More People

Years
  1. 2024 (1)
  2. 2019 (1)
  3. 2016 (1)
  4. 2012 (2)
  5. 2011 (1)
Publications
  1. Annals of Oncology (2)
  2. Journal of Thoracic Oncology (2)
  3. Clinical Cancer Research (1)
  4. Nature Genetics (1)
Publishers
  1. Elsevier Inc. (2)
  2. Oxford University Press (2)
  3. American Association for Cancer Research (1)
  4. Nature Publishing Group (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Distinct clinical course of EGFR-mutant resected lung cancers: Results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Journal Article

    D'Angelo, S. P.; Janjigian, Y. Y.; Ahye, N.; Riely, G. J.; Chaft, J. E.; Sima, C. S.; Shen, R.; Zheng, J.; Dycoco, J.; Kris, M. G.; more...
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers
    Journal Article

    Dogan, S.; Shen, R.; Ang, D. C.; Johnson, M. L.; D'Angelo, S. P.; Paik, P. K.; Brzostowski, E. B.; Riely, G. J.; Kris, M. G.; Zakowski, M. F.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
    Journal Article

    Janjigian, Y. Y.; Park, B. J.; Zakowski, M. F.; Ladanyi, M.; Pao, W.; D'Angelo, S. P.; Kris, M. G.; Shen, R.; Zheng, J.; Azzoli, C. G.
    Journal of Thoracic Oncology (2011)

    Fulltext@MSK | Save